GLAXF
GSK plc OTC$27.18
Mkt Cap $108.5B
52w Low $17.15
70.0% of range
52w High $31.48
50d MA $27.73
200d MA $23.70
P/E (TTM)
18.5x
EV/EBITDA
7.4x
P/B
6.6x
Debt/Equity
1.1x
ROE
37.2%
P/FCF
12.4x
RSI (14)
—
ATR (14)
—
Beta
0.35
50d MA
$27.73
200d MA
$23.70
Avg Volume
1.8K
About
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The compa…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | TNS | 0.57 | 0.61 | +7.9% | 27.08 | -5.9% | -3.9% | +0.4% | — | — | — | — |
| Feb 4, 2026 | TNS | 0.32 | 0.34 | +7.1% | 27.63 | +4.2% | +6.2% | +1.8% | +2.2% | +6.9% | +9.1% | — |
| Oct 29, 2025 | TNS | 0.63 | 0.49 | -22.2% | 21.74 | +7.2% | +7.2% | +0.7% | +5.6% | +0.3% | +7.9% | — |
| Jul 30, 2025 | TNS | 0.59 | 0.48 | -19.6% | 18.76 | -5.5% | +1.4% | +1.4% | +1.9% | -0.9% | -3.2% | — |
| Apr 29, 2025 | TNS | 54.81 | 59.65 | +8.8% | 18.81 | +0.0% | +0.0% | +10.8% | +0.7% | +6.6% | +0.7% | — |
| Feb 5, 2025 | TNS | 0.31 | 28.74 | +9171.0% | 18.38 | +0.9% | +0.9% | -2.3% | -0.6% | -3.4% | +2.3% | — |
| Oct 30, 2024 | TNS | 43.20 | 49.70 | +15.0% | 18.32 | -1.7% | -1.4% | -1.4% | -3.1% | -5.3% | -5.3% | — |
| Jul 31, 2024 | TNS | 38.46 | 43.40 | +12.8% | 19.29 | +3.7% | +3.7% | +0.0% | +0.0% | +0.0% | +7.3% | — |
| May 1, 2024 | TNS | 36.97 | 43.10 | +16.6% | 21.00 | +0.0% | +0.0% | +0.7% | +0.7% | +4.9% | +4.0% | — |
| Jan 31, 2024 | TNS | 29.96 | 28.90 | -3.5% | 20.55 | -1.3% | -2.7% | -3.4% | -1.3% | +1.4% | +1.4% | — |
Data updated apr 27, 2026 7:43pm
· Source: massive.com